Glenmark Launches RYALTRIS in Brazil for Allergic Rhinitis

SAO PAULO and MUMBAI — Glenmark Specialty S.A., a wholly-owned subsidiary of Glenmark Pharmaceuticals Ltd., officially launched RYALTRIS nasal spray in Brazil on September 11, 2026, to treat moderate to severe symptoms of allergic rhinitis in adults and adolescents aged 12 and older. The commercial rollout follows regulatory clearance granted earlier in the year by the Brazilian Health Regulatory Agency (ANVISA). This market entry strengthens the company's global respiratory footprint, offering a critical therapeutic option for an estimated 40 to 60 million people suffering from chronic nasal allergies across Brazil.

Regulatory Milestone and Market Expansion

The market entry in Brazil marks a major step forward for Glenmark's international commercial strategy. According to regulatory filings submitted to the National Stock Exchange of India Limited (NSE) and BSE Limited, the launch follows formal approval from ANVISA.

RYALTRIS represents Glenmark’s first globally commercialized branded innovative product. With this expansion, the therapy is now cleared or available across 57 markets worldwide, including major jurisdictions such as the United States, the European Union, the United Kingdom, Australia, South Korea, Russia, and China.

Clinical Profile and Public Health Impact

Allergic rhinitis remains a highly prevalent chronic condition in Brazil, affecting roughly 20% to 30% of the national population. The introduction of RYALTRIS delivers the first olopatadine-containing intranasal combination therapy in the country.

The formulation pairs an antihistamine (olopatadine hydrochloride) with a corticosteroid (mometasone furoate) inside a single nasal spray device. This dual-action mechanism targets moderate to severe symptoms more efficiently than single-agent therapies, addressing a major unmet need for patients and clinicians throughout Latin America's largest healthcare market.

Official Statements and Executive Commentary

Company executives highlighted that the launch underscores a broader corporate commitment to science-led respiratory care.

"The launch of RYALTRIS in Brazil marks a significant milestone for our innovative respiratory portfolio and reflects our continued commitment to advancing respiratory care through science-led innovation and a patient-centric approach," stated Marco Cerato, Executive Vice President and Global Head of Innovative Business at Glenmark Pharmaceuticals. "As the largest healthcare market in Latin America, Brazil provides a strategic opportunity to bring this differentiated treatment option to patients and healthcare professionals."

Why It Matters

For patients, the availability of a dual-action combination spray reduces medication burden by consolidating two distinct classes of drugs into a single daily administration. For consumers and healthcare providers in Brazil, the rollout expands access to advanced international treatment standards locally. For investors, the commercialization in Latin America's primary pharmaceutical hub reinforces Glenmark's revenue diversification strategy within its high-margin respiratory portfolio.

Key Facts at a Glance

• Product & Indication: RYALTRIS nasal spray for moderate to severe allergic rhinitis in individuals aged 12 and older.

• Regulatory Body: Approved by the Brazilian Health Regulatory Agency (ANVISA).

• Disease Burden: Affects an estimated 20% to 30% of Brazil's population (roughly 40 to 60 million people).

• Formulation: A fixed-dose combination of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid).

• Global Reach: Now commercialized or approved across 57 global markets, including the US, EU, UK, and China.

Frequently Asked Questions

What is RYALTRIS nasal spray?

RYALTRIS is a fixed-dose combination nasal spray containing an antihistamine and a corticosteroid designed to treat moderate to severe allergic rhinitis.

Who manufactures and distributes RYALTRis in Brazil?

The product is distributed by Glenmark Specialty S.A., a wholly-owned subsidiary of Glenmark Pharmaceuticals Ltd.

Which patients are eligible for this treatment?

The therapy is indicated for adults and adolescents aged 12 years and older suffering from allergic rhinitis symptoms.

How widespread is allergic rhinitis in Brazil?

Medical estimates indicate that allergic rhinitis affects between 20% and 30% of the Brazilian population, translating to roughly 40 to 60 million citizens.

Source: Glenmark Pharmaceuticals Limited Stock Exchange Filing & Press Release, ANVISA Regulatory Database, National Stock Exchange of India, BSE Limited.